Biosimilar substitution on the table in Australia
This article was originally published in Scrip
Executive Summary
Australia's Pharmaceutical Benefits Advisory Committee (PBAC) is considering whether biosimilars could be marked as equivalent to their reference drug in the Schedule of Pharmaceutical Benefits – a move that would allow biosimilar substitution at the pharmacy level.